Page last updated: 2024-11-04

carbazochrome

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbazochrome is a synthetic derivative of adrenaline that is structurally similar to the naturally occurring compound adrenochrome. It was initially investigated for its potential hemostatic properties and was used in the past to treat bleeding, particularly in cases of capillary fragility. However, its clinical use has largely been abandoned due to concerns regarding its safety and efficacy. The synthesis of carbazochrome typically involves oxidation of adrenaline with chromic acid. Research has explored its effects on blood clotting, its potential to reduce capillary permeability, and its possible therapeutic applications in conditions such as retinal hemorrhage and capillary fragility. Despite the initial interest, further research is needed to validate its clinical benefits and address potential safety concerns.'

carbazochrome: a hemostatic which increases capillary resistance & activates platelet factors, Note: Adona is a multimeaning tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2557
CHEMBL ID2051960
CHEMBL ID4789892
CHEBI ID31349
SCHEMBL ID11036230
SCHEMBL ID506178
MeSH IDM0198343

Synonyms (93)

Synonym
3-hydroxy-1-methyl-5-semicarbazono-6(5h)-indolinon
adrenoxil
carbazochromum [inn-latin]
carbazocromo [inn-spanish]
adrenochrome monosemicarbazone
adrenostan
3-hydroxy-1-methyl-5,6-inodlindionsemicarbazon
einecs 200-717-0
hydrazinecarboxamide, 2-(1,2,3,6-tetrahydro-3-hydroxy-1-methyl-6-oxo-5h-indol-5-ylidene)-
cromosil
carbazochrome [inn:jan]
l 502
cromoxin
adrenochrome monosemicarbazon
nsc 73742
5,6-indolinedione, 3-hydroxy-1-methyl-, 5-semicarbazone
3-hydroxy-1-methyl-5,6-indolinedione semicarbazone
apara
adedolon
adrenoxyl
adchnon
adrokson
nsc73742
adroxon
nsc-73742
carbazochrome
69-81-8
cromadrenal
adrenochrome semicarbazone
5, 3-hydroxy-1-methyl-, 5-semicarbazone
carbazochrom
adrezon
sangostasin
sangostazin
adrenostazin
adenocrome monosemicarbazone
hydrazinecarboxamide,2,3,6-tetrahydro-3-hydroxy-1-methyl-6-oxo-5h-indol-5-ylidene)-
cartabes
D01864
carbazochrome (jan/inn)
NCGC00164521-01
A0176
ZINC03871875
[(z)-(3-hydroxy-1-methyl-6-oxo-2,3-dihydroindol-5-ylidene)amino]urea
dtxcid00809636
cas-69-81-8
tox21_113160
dtxsid3048310 ,
AKOS024319075
CHEMBL2051960
carbazochromum
unii-81f061rqs4
carbazocromo
81f061rqs4 ,
AKOS015896532
S5084
carbazochrome [jan]
carbazochrome [mi]
carbazochrome [who-dd]
carbazochrome [inn]
adrenochrome monosemicarbazone [mi]
carbazochrome [mart.]
SCHEMBL11036230
adrenochromsemicarbazon
5,6-dihydro-3-hydroxy-1-methyl-5,6-indolindion-5-semicarbazon
SCHEMBL506178
NCGC00344541-01
2-(3-hydroxy-1-methyl-6-oxo-2,3-dihydro-1h-indol-5(6h)-ylidene)hydrazinecarboxamide
XSXCZNVKFKNLPR-SDQBBNPISA-N
3-hydroxy-1-methyl-2,3-dihydro-1h-indole-5,6-dione 5-semicarbazone #
2,3-dihydro-3-hydroxy-1-methyl-1h-indole-5,6-dione-5-semicarbazone
W-104582
AC-31089
DB09012
mfcd00130253
CHEBI:31349 ,
AKOS030242682
CS-0013486
HY-B1587
{[(5e)-3-hydroxy-1-methyl-6-oxo-2,3,5,6-tetrahydro-1h-indol-5-ylidene]amino}urea
DS-4533
BCP15360
(e)-2-(3-hydroxy-1-methyl-6-oxo-2,3-dihydro-1h-indol-5(6h)-ylidene)hydrazinecarboxamide
carbazochrome,(s)
Q1104521
CHEMBL4789892
AMY39497
CCG-266833
adrenochrome monosemicarbazone; adrenostazin; adrenoxyl; adrezon
(3,6-dihydroxy-1-methyl-2,3-dihydroindol-5-yl)iminourea
H11624
SY057431
SB67333

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A highly selective and sensitive liquid chromatography coupled with atmospheric pressure chemical ionization tandem mass spectrometry (LC-APCI-MS-MS) was developed and validated for the quantitation and pharmacokinetic study of carbazochrome sodium sulfonate in human plasma."( Development and validation of a robust LC-MS-MS with atmospheric pressure chemical ionization for quantitation of carbazochrome sodium sulfonate in human plasma: application to a pharmacokinetic study.
Hang, T; Song, M; Wang, L; Wen, A; Yang, L; Zhao, H, 2010
)
0.75

Compound-Compound Interactions

ExcerptReferenceRelevance
"The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
1.35
"CSS combined with TXA can effectively reduce perioperative blood loss and immune response compared to TXA."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
1.11
" In addition, CSS combined with TXA is better than TXA alone in terms of improving postoperative hip pain and reducing the level of inflammatory factors."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
1.11

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Four simple, accurate, sensitive and precise spectrophotometric methods were developed and validated for simultaneous determination of Troxerutin (TXN) and Carbazochrome (CZM) in their bulk powders, laboratory prepared mixtures and pharmaceutical dosage forms."( Validated spectrophotometric methods for simultaneous determination of troxerutin and carbazochrome in dosage form.
Al-Ghobashy, MA; Ghoniem, NS; Hegazy, MA; Khattab, FI; Ramadan, NK, 2015
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency26.83700.01237.983543.2770AID1645841
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (55.79)18.7374
1990's9 (9.47)18.2507
2000's8 (8.42)29.6817
2010's15 (15.79)24.3611
2020's10 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.42 (24.57)
Research Supply Index4.82 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index85.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (16.04%)5.53%
Reviews2 (1.89%)6.00%
Case Studies5 (4.72%)4.05%
Observational1 (0.94%)0.25%
Other81 (76.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]